Moreover, while synergistic apoptosis with combined IR or TMZ and BCL-XL inhibition was exclusive to p53 WT tumours, functional BH3 profiling of apoptotic potential was also required to predict response to the drug combination, both in vitro and in vivo. This evidence concerns the gene BCL2L1 and neoplasm.